Register Now

Section 912: Potential Threat to Food Innovation

 

Are you up-to-date on Section 912 and the potential threat to food innovation? Tucked into a law recently passed by Congress is a little known prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.

The provision, known as Section 912, is now in effect and prohibits the addition to a food of an approved drug. It also prohibits the addition of a drug for which substantial clinical trials have been executed and made public. Food manufacturers must look at Section 912 closely to determine how it could affect their existing portfolios and their product development strategy.

You will better understand:

Intended Audience(s): Product Developers, Management, Sales & Marketing, Research Staff, Regulators, Academics, Students
Learning Level(s): Beginner, Intermediate, and Advanced
Member Registration Fee: $55
Presentation Date: 09/24/09 12:00 AM

Faculty:

Dr David H Bechtel, CFS
VP NJ Office
Cantox US Inc

Diane Barber McColl
Director
Hyman, Phelps & McNamara PC

Ashley Roberts PHD
VP Food & Nutrition Grp
Intertek Cantox

Michael Landa
Deputy Director for Regulatory Affairs
FDA-CFSAN